Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000014402 | SCV000696633 | pathogenic | Amyloidosis, hereditary systemic 1 | 2016-08-16 | criteria provided, single submitter | clinical testing | Variant summary: The TTR c.424_426delGTC (p.Val142del) variant causes an in-frame deletion in the last exon. The variant of interest was not observed in controls (ExAC, 1000 Gs, or ESP) and has been reported in multiple affected individuals including a large family in which the variant segregates with disease (Munar-Ques_2001). The variant of interest has been classified as pathogenic/likely pathogenic by multiple reputable databases/clinical laboratories. Therefore, the variant of interest has been classified as Pathogenic. |
| Labcorp Genetics |
RCV000014402 | SCV001410440 | pathogenic | Amyloidosis, hereditary systemic 1 | 2023-12-20 | criteria provided, single submitter | clinical testing | This variant, c.424_426del, results in the deletion of 1 amino acid(s) of the TTR protein (p.Val142del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) (PMID: 9191784, 11140845, 24101130). It has also been observed to segregate with disease in related individuals. This variant is also known as deltaV122. ClinVar contains an entry for this variant (Variation ID: 13460). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects TTR function (PMID: 15820680). This variant disrupts the p.Val142 amino acid residue in TTR. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12050338, 15820680, 17503405, 18276611, 19781421, 22745357, 24184229, 25846356). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Mayo Clinic Laboratories, |
RCV004791221 | SCV005413292 | pathogenic | not provided | 2023-11-03 | criteria provided, single submitter | clinical testing | PP1, PP4, PM2_moderate, PM4, PS3_moderate, PS4 |
| OMIM | RCV000014402 | SCV000034651 | pathogenic | Amyloidosis, hereditary systemic 1 | 2000-11-01 | no assertion criteria provided | literature only | |
| Laboratory for Molecular Medicine, |
RCV000014402 | SCV000060032 | likely pathogenic | Amyloidosis, hereditary systemic 1 | 2008-09-02 | no assertion criteria provided | clinical testing |